Abstract

The alarming phenomenon of antibiotic resistance in Helicobacter pylori suggests to pay close attention in the treatment. In particular, the clarithromycin resistance in H. pylori was designed by the World Health Organization (WHO) as high priority for antibiotic research in 2017 [1]. In Italy, the overall primary resistance to clarithromycin can be detected in 35.2% of cases; in France, it can be detected in 26% of cases, while in Spain, clarithromycin resistance is present in 27.2% of strains [2–4].Natural/innovative strategies, as well as novel potentiators to restore the antibiotic susceptibility in resistant strains, could be used to improve the efficacy of H. pylori eradication, and they could be worthy to change attitude of medicine in dealing with the challenge known as H. pylori [5, 6].Obviously, these therapeutic strategies should be used in patients infected by resistant H. pylori and in presence of coinfection with other pathogens responsible to develop severe gastric diseases [7].On the basis of this evidence, the aim of this special issue was to collect research manuscripts and review manuscripts, case reports, and literature reviews with the objective to expand our knowledge in this innovative field.
Lingua originaleEnglish
pagine (da-a)1-2
Numero di pagine2
RivistaCANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY
Volume2019
Stato di pubblicazionePublished - 2019

Fingerprint

Helicobacter Infections
Helicobacter pylori
Clarithromycin
Manuscripts
Anti-Bacterial Agents
Therapeutics
Stomach Diseases
Microbial Drug Resistance
Coinfection
Research
Spain
Italy
France
Medicine

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cita questo

@article{34ee2d7e73bf4459926d7003f6a2e2e9,
title = "Helicobacter pylori: Infection and new perspective for the treatment",
abstract = "The alarming phenomenon of antibiotic resistance in Helicobacter pylori suggests to pay close attention in the treatment. In particular, the clarithromycin resistance in H. pylori was designed by the World Health Organization (WHO) as high priority for antibiotic research in 2017 [1]. In Italy, the overall primary resistance to clarithromycin can be detected in 35.2{\%} of cases; in France, it can be detected in 26{\%} of cases, while in Spain, clarithromycin resistance is present in 27.2{\%} of strains [2–4].Natural/innovative strategies, as well as novel potentiators to restore the antibiotic susceptibility in resistant strains, could be used to improve the efficacy of H. pylori eradication, and they could be worthy to change attitude of medicine in dealing with the challenge known as H. pylori [5, 6].Obviously, these therapeutic strategies should be used in patients infected by resistant H. pylori and in presence of coinfection with other pathogens responsible to develop severe gastric diseases [7].On the basis of this evidence, the aim of this special issue was to collect research manuscripts and review manuscripts, case reports, and literature reviews with the objective to expand our knowledge in this innovative field.",
author = "Fasciana, {Teresa Maria Assunta} and {Di Carlo}, Paola and Ahlem Jouini and {Di Giulio}, Mara",
year = "2019",
language = "English",
volume = "2019",
pages = "1--2",
journal = "CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY",
issn = "1918-1493",

}

TY - JOUR

T1 - Helicobacter pylori: Infection and new perspective for the treatment

AU - Fasciana, Teresa Maria Assunta

AU - Di Carlo, Paola

AU - Jouini, Ahlem

AU - Di Giulio, Mara

PY - 2019

Y1 - 2019

N2 - The alarming phenomenon of antibiotic resistance in Helicobacter pylori suggests to pay close attention in the treatment. In particular, the clarithromycin resistance in H. pylori was designed by the World Health Organization (WHO) as high priority for antibiotic research in 2017 [1]. In Italy, the overall primary resistance to clarithromycin can be detected in 35.2% of cases; in France, it can be detected in 26% of cases, while in Spain, clarithromycin resistance is present in 27.2% of strains [2–4].Natural/innovative strategies, as well as novel potentiators to restore the antibiotic susceptibility in resistant strains, could be used to improve the efficacy of H. pylori eradication, and they could be worthy to change attitude of medicine in dealing with the challenge known as H. pylori [5, 6].Obviously, these therapeutic strategies should be used in patients infected by resistant H. pylori and in presence of coinfection with other pathogens responsible to develop severe gastric diseases [7].On the basis of this evidence, the aim of this special issue was to collect research manuscripts and review manuscripts, case reports, and literature reviews with the objective to expand our knowledge in this innovative field.

AB - The alarming phenomenon of antibiotic resistance in Helicobacter pylori suggests to pay close attention in the treatment. In particular, the clarithromycin resistance in H. pylori was designed by the World Health Organization (WHO) as high priority for antibiotic research in 2017 [1]. In Italy, the overall primary resistance to clarithromycin can be detected in 35.2% of cases; in France, it can be detected in 26% of cases, while in Spain, clarithromycin resistance is present in 27.2% of strains [2–4].Natural/innovative strategies, as well as novel potentiators to restore the antibiotic susceptibility in resistant strains, could be used to improve the efficacy of H. pylori eradication, and they could be worthy to change attitude of medicine in dealing with the challenge known as H. pylori [5, 6].Obviously, these therapeutic strategies should be used in patients infected by resistant H. pylori and in presence of coinfection with other pathogens responsible to develop severe gastric diseases [7].On the basis of this evidence, the aim of this special issue was to collect research manuscripts and review manuscripts, case reports, and literature reviews with the objective to expand our knowledge in this innovative field.

UR - http://hdl.handle.net/10447/367541

M3 - Article

VL - 2019

SP - 1

EP - 2

JO - CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY

JF - CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY

SN - 1918-1493

ER -